All In Biotech

Drug Trial Radar · NCT02391727

Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors

A Phase 1, Multi-center, Open-Label Dose Escalation Study of SYN004 in Patients With Solid Tumors to Evaluate the Safety, Immunogenicity and Pharmacokinetics of SYN004 Following Administration of Eight Intravenous Doses

Last checked: Nov 19, 2026Latest source record: Nov 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

May 2015

Primary completion

Oct 2018

Study completion Oct 2018

Sponsor

Lead sponsor
Synermore Biologics Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A first-in-human evaluation of SYN004, a monoclonal antibody that binds to the EGF receptor on cancer cells. Cetuximab, a marketed antibody, has been shown to be effective by inhibiting the growth of cancer cells thereby prolonging the life of patients who have received it. SYN004 is a closely related monoclonal antibody also binds to the EGF receptor in the same way. SYN004 might also inhibit cancer cells and prolong life but has been engineered to avoid some of the hypersensitivity reactions known to provoked by cetuximab.

Conditions

  • Colon Cancer, Breast Cancer, Cancer of the Head and Neck

Interventions

  • SYN004Biological

    subjects who have received effective treatment for their cancers are eligible

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with adverse eventsTime frame: 28 days of last SYN004 Administration

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Ochsner Medical Center

    New Orleans, Louisiana

  • Washington University Medical Center

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.